News Related to Resistant Hypertension

Related coverage linked through entity extraction aliases.

Baxfendy approved in the US for hypertension treatment

May 18, 2026

Baxfendy was approved in the US for hypertension in adults not adequately controlled on other antihypertensive medicines. The approval was based on Phase III BaxHTN results showing significant systolic blood pressure reductions.

CVRx enrolls first patient in BENEFIT-HF heart failure trial

May 05, 2026

CVRx announced first-patient enrollment in the BENEFIT-HF trial, a 2,500-patient heart failure study across about 150 U.S. and German centers. The trial will evaluate all-cause mortality and heart failure decompensation events through 2032.